Malaria - World Health Organization (WHO) There are 5 Plasmodium parasite species that cause malaria in humans and 2 of these species – P falciparum and P vivax – pose the greatest threat P falciparum is the deadliest malaria parasite and the most prevalent on the African continent P vivax is the dominant malaria parasite in most countries outside of sub-Saharan Africa
Malaria - World Health Organization (WHO) Malaria is a treatable disease Artemisinin-based combination therapies (ACTs) are the most effective antimalarial medicines available today and the mainstay of recommended treatment for Plasmodium falciparum malaria, the deadliest malaria parasite globally
Malaria - World Health Organization (WHO) Malaria is a preventable and treatable disease Early diagnosis and treatment of malaria reduces disease and prevents deaths, and also contributes to reducing transmission The best available treatment, particularly for Plasmodium falciparum malaria, is artemisinin-based combination therapy (ACT) Antimalarial medicines can also be used to
Paludisme - World Health Organization (WHO) Sur les cinq espèces de parasites du genre Plasmodium responsables du paludisme chez l’être humain, P falciparum et P vivax sont les plus dangereux P falciparum est le parasite provoquant le plus de décès et aussi le plus répandu sur le continent africain, tandis que P vivax est l’espèce dominante dans la plupart des pays en
Paludismo - World Health Organization (WHO) Hay cinco especies de parásitos Plasmodium que pueden provocar paludismo en el ser humano, dos de las cuales, Plasmodium falciparum y Plasmodium vivax, constituyen la mayor amenaza P falciparum es el parásito del paludismo más mortífero y el más prevalente en el continente africano
Diagnostic tests for detecting risk of Plasmodium vivax relapse Relapsing malaria caused by Plasmodium vivax parasites poses a significant challenge to global malaria elimination efforts About one third of the population remains at risk of contracting P vivax malaria, and 85% of P vivax infections stem from reactivated latent parasites, leading to chronic anaemia and increased morbidity and mortality
Control and elimination of Plasmodium vivax malaria – A technical brief Confronting Plasmodium vivax malaria is the advocacy companion of the technical brief It examines why action on P vivax is needed, the challenges the disease poses, what should be done against it and the resulting health and economic benefits of P vivax control and elimination
Paludisme - World Health Organization (WHO) Dans la Région OMS des Amériques, le parasite Plasmodium vivax prédomine C’est en Afrique subsaharienne que le risque de paludisme est le plus élevé ; en 2023, plus de la moitié des décès dus au paludisme dans le monde se concentraient dans quatre pays de cette région : le Nigéria (30,9 %), la République démocratique du Congo (11
Global Malaria Programme - World Health Organization (WHO) The best available treatment, particularly for Plasmodium falciparum malaria, is artemisinin-based combination therapy (ACT) The primary objective of treatment is curing the infection by ensuring the rapid and full elimination of Plasmodium parasites from a patient’s bloodstream This also prevent an uncomplicated case of malaria from
Malaria - World Health Organization (WHO) Six identified species of the Plasmodium protozoan parasite can infect and cause disease in humans (P falciparum, P vivax, P ovale curtisi, P ovale wallikeri, P malariae and P knowlesi) P falciparum accounts for over 90% of all malaria-attributable deaths